Hypoxia-inducible factors in the first trimester human lung

被引:51
|
作者
Groenman, Frederick
Rutter, Martin
Caniggia, Isabella
Tibboel, Dick
Post, Martin
机构
[1] Univ Toronto, Lung Biol Res Physiol & Expt Res Program,Dept Ped, Inst Res,Hosp Sick Children, Canadian Inst Hlth Res,Grp Lung Dev, Toronto, ON M5G 1X8, Canada
[2] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada
[3] Erasmus MC Sophia, Dept Pediat Surg, Rotterdam, Netherlands
[4] Univ Toronto, Mt Sinai Hosp, Dept Obstet & Gynaecol, Toronto, ON M5G 1X5, Canada
关键词
pulmonary vascularization; hypoxia-inducible factor; development; human;
D O I
10.1369/jhc.6A7129.2006
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Lung development takes place in a relatively low-oxygen environment, which is beneficial for lung organogenesis, including vascular development. Hypoxia-inclucible factor (HIF)-1 plays an important role in mediating oxygen-regulated events. HIF-1 is stable and initiates gene transcription under hypoxia, whereas in normoxia, interaction with the von Hippel-Linclau (VHL) tumor suppressor protein leads to rapid degradation of the HIF-1 alpha subunit. Interaction with VHL requires hydroxylation of HIF-10-proline residues by prolyl hydroxylases (PHDs). We investigated the expression of the various components regulating HIF-1 alpha stability in first trimester (8-14weeks) human lungs. Spatial expression was assessed by immunohistochemistry and temporal expression by quantitative PCR. Immunoreactivity for PHD1, PHD3, and seven in absentia homolog (SIAH)1 was noted in the pulmonary epithelium. PHD2 was not expressed in the airway epithelium, but in the lung parenchyma. HIF-1(X and vascular endothelial growth factor (VEGF) immunoreactivity were primarily detected in the branching epithelium. HIF-2 alpha and ARNT proteins localized to the developing epithelium as well as mesenchymal, most likely vascular, structures in the parenchyma. VEGF receptor 2 (VEGFR2) was found in the subepithelium as well as in vascular structures of the mesenchyme. All components of the VEC complex (VHL, NEDD8, and Cullin2) were found in the epithelium. Quantitative PCR analysis demonstrated that VEGF, VEGFR1, HIF-1 alpha, HIF-2 alpha, ARNT, PHD1, PHD2, PHD3, and SIAH1 gene expression was constant during early pulmonary organogenesis. Cumulatively, the data suggest that the lung develops in a low-oxygen environment that allows for proper vascular development through HIF-regulated pathways.
引用
收藏
页码:355 / 363
页数:9
相关论文
共 50 条
  • [31] The role of hypoxia-inducible factors in cancer
    Maynard, M. A.
    Ohh, M.
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2007, 64 (16) : 2170 - 2180
  • [32] Hypoxia-Inducible Factors in Physiology and Medicine
    Semenza, Gregg L.
    CELL, 2012, 148 (03) : 399 - 408
  • [33] The role of hypoxia-inducible factors in cancer
    M. A. Maynard
    M. Ohh
    Cellular and Molecular Life Sciences, 2007, 64 : 2170 - 2180
  • [34] Hypoxia-inducible factors in hepatocellular carcinoma
    Guo, Yang
    Xiao, Zunqiang
    Yang, Liu
    Gao, Yuling
    Zhu, Qiaojuan
    Hu, Linjun
    Huang, Dongsheng
    Xu, Qiuran
    ONCOLOGY REPORTS, 2020, 43 (01) : 3 - 15
  • [35] The role of hypoxia-inducible factors in tumorigenesis
    E B Rankin
    A J Giaccia
    Cell Death & Differentiation, 2008, 15 : 678 - 685
  • [36] Endocrine targets of hypoxia-inducible factors
    Lee, Hsiu-Chi
    Tsai, Shaw-Jenq
    JOURNAL OF ENDOCRINOLOGY, 2017, 234 (01) : R53 - R65
  • [37] Hypoxia and Hypoxia-Inducible Factors: Master Regulators of Metastasis
    Lu, Xin
    Kang, Yibin
    CLINICAL CANCER RESEARCH, 2010, 16 (24) : 5928 - 5935
  • [38] Hypoxia, hypoxia-inducible factors and inflammatory bowel diseases
    Hou, Fei
    Bian, Xixi
    Jing, Dehuai
    Gao, Huikuan
    Zhu, Fengqin
    GASTROENTEROLOGY REPORT, 2023, 12
  • [39] Hypoxia and Hypoxia-Inducible Factors in Kidney Injury and Repair
    Shu, Shaoqun
    Wang, Ying
    Zheng, Meiling
    Liu, Zhiwen
    Cai, Juan
    Tang, Chengyuan
    Dong, Zheng
    CELLS, 2019, 8 (03)
  • [40] Hypoxia and hypoxia-inducible factors in chronic kidney disease
    Tanaka S.
    Tanaka T.
    Nangaku M.
    Renal Replacement Therapy, 2 (1)